ArticleCureus2025
Shortening the Journey to Cure: A Quasi-experimental Trial Comparing Seven-Day and 14-Day Primaquine Radical Therapy for Vivax Malaria.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction Because dormant liver-stage hypnozoites can cause recurrence, Plasmodium vivax (P. vivax) malaria poses serious problems. Although the standard treatment for radical cure is 14 days of primaquine medication, this lengthy course of treatment frequently causes poor adherence. In contrast to the typical 14-day low-dose regimen, this study assesses the effectiveness, safety, and adherence of a condensed seven-day high-dose primaquine regimen. Objectives The objectives of this study are to assess and compare the efficacy of seven-day high-dose primaquine therapy with 14-day low-dose therapy. Methodology Over nine months, this quasi-experimental study was carried out at the Hayatabad Medical Complex's General Medicine Unit in Peshawar, Pakistan. One hundred patients with confirmed P. vivax malaria, ages 18 to 76, were split into two groups. Group A (intervention group; n=50) was given primaquine (1 mg/kg/day) for seven days, whereas Group B (control group; n=50) was given primaquine (0.5 mg/kg/day) for 14 days. Assessments were conducted again on days 14, 28, 60, and 90 to look for relapse of febrile illness and/or parasitemia. IBM SPSS Statistics for Windows, Version 23 (Released 2015; IBM Corp., Armonk, New York, United States) was used to analyse treatment outcomes, such as adverse events, adherence, and illness recurrence. Results The disease recurrence rate was substantially lower in Group A (2%), which was receiving a shorter course of therapy, as compared to Group B (26%), which was given 14-day therapy. Chi-square analyses show significance with a p-value of 0.012. Additionally, the shorter regimen had a higher adherence rate (94%) compared to the 14-day regimen (76%) (p = 0.012). Both regimens were well tolerated, with a slightly increased occurrence of very mild gastrointestinal symptoms in Group A. No serious side effects were noted. Conclusion Similar efficacy to the conventional 14-day therapy is provided by the seven-day high-dose primaquine regimen, which also has an acceptable safety profile and much-improved adherence. In areas with limited resources where adherence to prolonged therapy is difficult, this condensed regimen may improve treatment outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.